专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011122922A2 LONG-ACTING HUMAN FOLLICLE-STIMULATING HORMONE FORMULATION USING IMMUNOGLOBULIN FRAGMENT 审中-公开
标题翻译：使用免疫抑制蛋白片段长效人体激素激素配方
公开(公告)号：WO2011122922A2
公开(公告)日：2011-10-06
申请号：PCT/KR2011/002332
申请日：2011-04-04
申请人： HANMI HOLDINGS CO., LTD. , KIM, Chang Hwan , HONG, Sung Kap , LEE, Byung Sun , KWAK, Soo Young , LEE, Mi Ji , CHOI, In Young , KWON, Se Chang
发明人： KIM, Chang Hwan , HONG, Sung Kap , LEE, Byung Sun , KWAK, Soo Young , LEE, Mi Ji , CHOI, In Young , KWON, Se Chang
IPC分类号： A61K9/22 , A61K47/40 , A61K47/34
CPC分类号： A61K47/48215 , A61K47/60 , A61K47/68
摘要： The present invention relates to a long-acting human follicle-stimulating hormone formulation having improved in vivo duration and stability, comprising a human follicle-stimulating hormone conjugate that is prepared by covalently linking human follicle-stimulating hormone with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting human follicle-stimulating hormone formulation of the present invention maintains in vivo activity of human follicle-stimulating hormone at a relatively high level and remarkably increases the serum half-life thereof.
摘要翻译：本发明涉及具有改善的体内持续时间和稳定性的长效促卵泡激素制剂，其包含人促卵泡激素缀合物，其通过非激素共价连接人卵泡刺激激素与免疫球蛋白Fc区而制备 - 肽基聚合物及其制备方法。本发明的长效人促卵泡激素制剂在较高水平维持人卵泡刺激激素的体内活性，并且显着增加其血清半衰期。

2. 发明申请

WO2012057527A2 METHOD FOR MASS PRODUCTION OF FACTOR VII/VIIA 审中-公开
标题翻译：大量生产因子VII / VIIA的方法
公开(公告)号：WO2012057527A2
公开(公告)日：2012-05-03
申请号：PCT/KR2011/008040
申请日：2011-10-26
申请人： HANMI HOLDINGS CO., LTD. , KIM, Chang Hwan , HONG, Sung Kap , LEE, Byung Sun , HONG, Sung Hwan , KWON, Se Chang
发明人： KIM, Chang Hwan , HONG, Sung Kap , LEE, Byung Sun , HONG, Sung Hwan , KWON, Se Chang
IPC分类号： C12N15/85 , C12N15/12 , C07K14/745
CPC分类号： C12N9/6437 , C07K14/745 , C12N15/85 , C12N2830/85
摘要： Disclosed is a method for the mass production of human coagulation factor VII. The method comprises a) constructing an expression vector carrying i) a dihydrofolate reductase promoter devoid of one or more CCGCC repeat sequences from the GC-rich region thereof and a dihydrofolate reductase (DHFR) gene operably linked thereto and ii) a cytomegalovirus (CMV) promoter and a human coagulation factor VII gene operably linked thereto; b) transfecting the expression vector of step a) into an animal cell line; c) culturing the transfected animal cell line of step b) in the presence of a dihydrofolate reductase inhibitor to select cells which express human coagulation factor VII with high efficiency; and d) adding sodium butyrate to the selected animal cells of step c), and a cell line for mass production of human coagulation factor VII. Employing a vector carrying a DHFR promoter devoid of GC-rich repeating sequences, the method can produce human coagulation factor VII at high efficiency on a large scale, which contributes to the treatment of hemophilia.
摘要翻译：公开了用于大量生产人凝血因子VII的方法。该方法包括a）构建表达载体，其携带i）不含来自其富GC区的一个或多个CCGCC重复序列的二氢叶酸还原酶启动子和与其可操作连接的二氢叶酸还原酶（DHFR）基因，和ii）巨细胞病毒（CMV）启动子和与之可操作连接的人凝血因子VII基因; b）将步骤a）的表达载体转染到动物细胞系中; c）在二氢叶酸还原酶抑制剂存在下培养步骤b）的转染的动物细胞系以选择高效表达人凝血因子Ⅶ的细胞; 和d）向步骤c）的所选动物细胞中添加丁酸钠，以及用于大量生产人凝血因子VII的细胞系。使用携带不含富含GC的重复序列的DHFR启动子的载体，该方法可以大规模高效率地产生人凝血因子VII，这有助于治疗血友病。

3. 发明申请

WO2012002745A2 FACTOR VIIA COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT 审中-公开
标题翻译：因子VIIA复合物使用免疫抑制蛋白片段
公开(公告)号：WO2012002745A2
公开(公告)日：2012-01-05
申请号：PCT/KR2011/004796
申请日：2011-06-30
申请人： HANMI HOLDINGS CO., LTD , SONG, Dae Hae , LIM, Sung In , KIM, Chang Hwan , HONG, Sung Kap , IM, Dae Seong , KWON, Se Chang
发明人： SONG, Dae Hae , LIM, Sung In , KIM, Chang Hwan , HONG, Sung Kap , IM, Dae Seong , KWON, Se Chang
IPC分类号： A61K47/48 , A61K47/30 , C07K14/745 , C07K16/18
CPC分类号： C12N9/96 , A61K9/0019 , A61K47/68 , A61K47/6811 , A61K47/6889 , C07K14/745 , C07K2319/30
摘要： Disclosed are a blood coagulation factor complex in which FacVIIa, a non-peptidyl polymer and an immunoglobulin Fc region are bonded by covalent bonds, and the uses thereof. The FacVIIa complex guarantees the in vivo activity of FacVIIa and significantly enhances the serum half life of FacVIIa, so that it is useful for developing long-acting FacVIIa formulations which can improve the compliance of role behavior of patients whose blood does not coagulate.
摘要翻译：公开了其中FacVIIa，非肽基聚合物和免疫球蛋白Fc区通过共价键键合的凝血因子复合物及其用途。 FacVIIa复合物保证FacVIIa的体内活性，并显着增强FacVIIa的血清半衰期，因此它可用于开发长效FacVIIa制剂，可以改善血液不凝血的患者的作用行为的顺应性。

4. 发明申请

WO2011090305A3 LIQUID FORMULATIONS FOR LONG-ACTING G-CSF CONJUGATE 审中-公开
公开(公告)号：WO2011090305A3
公开(公告)日：2011-07-28
申请号：PCT/KR2011/000369
申请日：2011-01-18
申请人： HANMI HOLDINGS CO., LTD , LEE, Mi Ji , LEE, Jae Min , LEE, Byung Sun , BAE, Sung Min , KWON, Se Chang
发明人： LEE, Mi Ji , LEE, Jae Min , LEE, Byung Sun , BAE, Sung Min , KWON, Se Chang
IPC分类号： A61K9/38 , A61K9/08 , A61K9/14 , A61K47/42
摘要： Disclosed is a liquid formulation which allows long-acting G-CSF conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting G-CSF conjugates.

5. 发明申请

WO2012008779A2 A LIQUID FORMULATION OF LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE 审中-公开
标题翻译：长寿命人体生长激素联合液的液体配方
公开(公告)号：WO2012008779A2
公开(公告)日：2012-01-19
申请号：PCT/KR2011/005194
申请日：2011-07-14
申请人： HANMI HOLDINGS CO., LTD. , HONG, Sung Hee , LEE, Byung Sun , IM, Dae Seong , LEE, Jae Min , BAE, Sung Min , KWON, Se Chang
发明人： HONG, Sung Hee , LEE, Byung Sun , IM, Dae Seong , LEE, Jae Min , BAE, Sung Min , KWON, Se Chang
IPC分类号： A61K9/08 , A61K9/22 , A61K38/27 , A61K47/36
CPC分类号： A61K47/48415 , A61K9/0019 , A61K9/08 , A61K38/27 , A61K47/12 , A61K47/26 , A61K47/60 , A61K47/68 , C07K2319/30
摘要： Disclosed is a liquid formulation of long-acting human growth hormone (hGH) conjugate, free of albumin, which can guarantee the stability of the long-acting hGH conjugate when stored over a long period of time, wherein the long-acting human growth hormone conjugate includes a human growth hormone linked to an immunoglobulin Fc region, and has a prolonged in vivo stability compared to the native form. The liquid formulation of hGH conjugate including a pH 5.0~6.0 buffer, a sugar alcohol, a salt and a non-ionic surfactant is free of human serum albumin and other hazardous factors which are potentially contaminated with viruses, and can provide excellent storage stability customized for a long-acting hGH conjugate composed of an hGH polypeptide and an immunoglobulin Fc region which has higher molecular weight and in vivo durability, compared to the native.
摘要翻译：公开了长效人生长激素（hGH）缀合物的液体制剂，其不含白蛋白，其可以长期保存长效hGH缀合物的稳定性，其中长效人生长激素缀合物包括与免疫球蛋白Fc区连接的人生长激素，并且与天然形式相比具有延长的体内稳定性。包含pH 5.0〜6.0缓冲液，糖醇，盐和非离子表面活性剂的hGH缀合物的液体制剂不含人血清白蛋白和其他可能被病毒污染的危险因素，可提供优良的储存稳定性对于由hGH多肽和具有较高分子量和体内耐久性的免疫球蛋白Fc区组成的长效hGH缀合物，与天然产物相比。

6. 发明申请

WO2012011752A2 NOVEL LONG-ACTING GLUCAGON CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE PREVENTION AND TREATMENT OF OBESITY 审中-公开
标题翻译：新型长效胰高血糖素结合物及包含其的用于预防和治疗肥胖症的药物组合物
公开(公告)号：WO2012011752A2
公开(公告)日：2012-01-26
申请号：PCT/KR2011/005375
申请日：2011-07-21
申请人： HANMI HOLDINGS CO., LTD. , WOO, Young Eun , LEE, Jong Soo , SHEN, Ling Ai , KIM, Dae Jin , JUNG, Sung Youb , CHOI, In Young , KWON, Se Chang
发明人： WOO, Young Eun , LEE, Jong Soo , SHEN, Ling Ai , KIM, Dae Jin , JUNG, Sung Youb , CHOI, In Young , KWON, Se Chang
IPC分类号： A61K38/26 , A61K31/4164 , C07K14/605 , A61P3/04 , A61P3/00
CPC分类号： A61K47/48415 , A61K31/4164 , A61K38/26 , A61K45/06 , A61K47/68 , A61K47/6811 , A61K47/6883 , C07K14/605 , A61K2300/00
摘要： Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity.
摘要翻译：公开了一种新型长效胰高血糖素缀合物，其中胰高血糖素或其衍生物通过非肽接头共价连接至聚合物载体，以及包含其作为有效成分的药物组合物，其可用于预防和治疗肥胖症。由于本发明的长效胰高血糖素缀合物显示出改善的体内耐久性和稳定性，因此当与抗肥胖药组合使用时，可能诱导体重减轻和食物摄取减少的协同效应，而不引起任何副作用如血糖水平的波动。因此，本发明的长效肽缀合物对于预防和治疗肥胖是非常有效的。

7. 发明申请

WO2008048037A1 A NOVEL VECTOR AND EXPRESSION CELL LINE FOR MASS PRODUCTION OF RECOMBINANT PROTEIN AND A PROCESS OF PRODUCING RECOMBINANT PROTEIN USING SAME 审中-公开
标题翻译：用于生产重组蛋白质的新型载体和表达细胞系以及使用其生产重组蛋白的方法
公开(公告)号：WO2008048037A1
公开(公告)日：2008-04-24
申请号：PCT/KR2007/005064
申请日：2007-10-16
申请人： HANMI PHARMACEUTICAL CO., LTD. , CHOI, In Young , KIM, Chang Hwan , LEE, Hyun Ji , PARK, Seong Hee , KWON, Se Chang , LEE, Gwan Sun
发明人： CHOI, In Young , KIM, Chang Hwan , LEE, Hyun Ji , PARK, Seong Hee , KWON, Se Chang , LEE, Gwan Sun
IPC分类号： C12N15/63 , C12N15/79 , C12N15/09
CPC分类号： C12N9/003 , C12N15/85 , C12N2510/00
摘要： Disclosed herein is an inducible high-expression cassette comprising a dihydrofolate reductase (DHFR) promoter from which GC-rich repeat sequences are partially or entirely removed, the cassette capable of more effectively improving a gene amplification system. Also disclosed are an expression vector comprising the inducible expression cassette and optionally a gene encoding a recombinant protein of interest, an animal cell line transformed with the expression vector, and a method of mass producing and purifying a recombinant protein by culturing the transformant. The present invention enables the shortening of the time required to establish a cell line producing a recombinant protein of interest at high levels using a low concentration of a DHFR inhibitor, thereby allowing more effective production of the recombinant protein.
摘要翻译：本文公开了包含二氢叶酸还原酶（DHFR）启动子的诱导型高表达盒，从其中部分或全部除去富含GC的重复序列，所述盒能够更有效地改善基因扩增系统。还公开了包含可诱导表达盒和任选的编码目标重组蛋白的基因，用表达载体转化的动物细胞系的表达载体，以及通过培养转化体大量生产和纯化重组蛋白的方法。本发明能够缩短使用低浓度的DHFR抑制剂以高水平建立产生重组蛋白质的细胞系所需的时间，从而允许更有效地产生重组蛋白质。

8. 发明申请

WO2005047337A1 A PHARMACEUTICAL COMPOSITION COMPRISING AN IMMUNOGLOBULIN FC REGION AS A CARRIER 审中-公开
标题翻译：包含免疫球蛋白FC区域作为载体的药物组合物
公开(公告)号：WO2005047337A1
公开(公告)日：2005-05-26
申请号：PCT/KR2004/002945
申请日：2004-11-13
申请人： HANMI PHARM. IND. CO., LTD. , KIM, Young Min , SONG, Dae Hae , JUNG, Sung Youb , KIM, Chang Hwan , CHOI, In Young , KWON, Se Chang , LEE, Gwan Sun
发明人： KIM, Young Min , SONG, Dae Hae , JUNG, Sung Youb , KIM, Chang Hwan , CHOI, In Young , KWON, Se Chang , LEE, Gwan Sun
IPC分类号： C07K19/00
CPC分类号： A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.
摘要翻译：公开了免疫球蛋白Fc片段的新用途，更具体地，涉及包含免疫球蛋白Fc片段作为载体的药物组合物。包含作为载体的免疫球蛋白Fc片段的药物组合物显着延长了药物的血清半衰期，同时保持药物的体内活性在相对高的水平。此外，当药物是多肽药物时，与免疫球蛋白Fc片段和靶蛋白质的融合蛋白相比，药物组合物诱导免疫应答的风险较小，因此可用于开发各种多肽药物的长效制剂。

9. 发明申请

WO2011122921A2 AN INSULIN CONJUGATE USING AN IMMUNOGLOBULIN FRAGMENT 审中-公开
标题翻译：胰岛素联合使用免疫球蛋白片段
公开(公告)号：WO2011122921A2
公开(公告)日：2011-10-06
申请号：PCT/KR2011/002331
申请日：2011-04-04
申请人： HANMI HOLDINGS CO., LTD. , SONG, Dae Hae , SHIN, Jae Hee , PARK, Young Jin , IM, Dae Seong , BAE, Sung Min , KWON, Se Chang
发明人： SONG, Dae Hae , SHIN, Jae Hee , PARK, Young Jin , IM, Dae Seong , BAE, Sung Min , KWON, Se Chang
IPC分类号： A61K38/28 , A61K9/20 , A61K47/40 , A61K47/34
CPC分类号： A61K38/28 , A61K47/68 , A61K47/6883 , C07K14/62 , C07K2319/30
摘要： The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.
摘要翻译：本发明涉及具有改善的体内持续时间和稳定性的胰岛素缀合物，其通过非肽基聚合物共价连接胰岛素与免疫球蛋白Fc区，包含其的长效制剂及其制备方法制备。本发明的胰岛素结合物以较高水平保持肽的体内活性，并显着增加血清的半衰期，从而大大提高了胰岛素治疗后的药物依从性。

10. 发明申请

WO2011122923A2 LONG-ACTING INTERFERON BETA FORMULATION USING IMMUNOGLOBULIN FRAGMENT 审中-公开
标题翻译：使用免疫抑制蛋白片段的长效干扰素制剂
公开(公告)号：WO2011122923A2
公开(公告)日：2011-10-06
申请号：PCT/KR2011/002335
申请日：2011-04-04
申请人： HANMI HOLDINGS CO., LTD. , KIM, Dae Jin , KIM, Min Young , KIM, Jin Sun , HONG, Sung Hee , JUNG, Sung Youb , KWON, Se Chang
发明人： KIM, Dae Jin , KIM, Min Young , KIM, Jin Sun , HONG, Sung Hee , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： A61K9/22 , A61K9/20 , A61K38/21 , A61K47/34
CPC分类号： A61K38/215 , A61K47/68 , A61K47/6813 , A61K47/6835 , C07K14/565 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious.
摘要翻译：本发明涉及具有改善的体内持续时间和稳定性的长效型干扰素β制剂，其包含通过非肽基聚合物共价连接干扰素β与免疫球蛋白Fc区制备的干扰素β偶联物及其制备方法。本发明的长效干扰素β配方维持干扰素β的体内活性在相当高的水平，并显着提高其血清半衰期，从而被用于干扰素有效的各种疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式